PH motifs in PAR1&2 endow breast cancer growth

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kancharla, A ^a   Maoz, M ^a   Jaber, M ^a   Agranovich, D ^a   Peretz, T ^a   Grisaru Granovsky, S ^b   Uziely, B ^a   Bar Shavit, R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PLECKSTRIN; PLECKSTRIN HOMOLOGY; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG;

CANCER; GROWTH RESPONSE; PATHOLOGY; PH; PHYSIOLOGICAL RESPONSE; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLACENTAL EXTRAVILLOUS TROPHOBLAST; POINT MUTATION; PROTEIN BINDING; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TROPHOBLAST; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; GENE INACTIVATION; GENETICS; HCT116 CELL LINE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MCF 7 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PLACENTA; PREGNANCY; PROTEIN TERTIARY STRUCTURE; TUMOR INVASION; UDDER; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; GENE KNOCKOUT TECHNIQUES; HCT116 CELLS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; MAMMARY GLANDS, ANIMAL; MCF-7 CELLS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PLACENTA; PREGNANCY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, PAR-1; RECEPTOR, PAR-2; TROPHOBLASTS;

EID: 84948166420     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9853     Document Type: Article

References (69)

1. Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79-94 (2007).
2. Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47-60 (2011).
3. Feigin, M. E. Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. FEBS J. 280, 4729-4738 (2013).
4. Santos, R. A. et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA 100, 8258-8263 (2003).
5. Debnath, J., Walker, S. J. & Brugge, J. S. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J. Cell Biol. 163, 315-326 (2003).
6. Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895-904 (2006).
7. Lopez-Otin, C. & Hunter, T. The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 10, 278-292 (2010).
8. Coughlin, S. R. Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
9. Rasmussen, U. B. et al. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett. 288, 123-128 (1991).
10. Nystedt, S., Emilsson, K., Wahlestedt, C. & Sundelin, J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl Acad. Sci. USA 91, 9208-9212 (1994).
11. Adams, M. N. et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130, 248-282 (2011).
12. Soh, U. J., Dores, M. R., Chen, B. & Trejo, J. Signal transduction by protease-activated receptors. Br. J. Pharmacol. 160, 191-203 (2010).
13. Bar-Shavit, R. et al. PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. IUBMB Life 63, 397-402 (2011).
14. Booden, M. A., Eckert, L. B., Der, C. J. & Trejo, J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol. Cell Biol. 24, 1990-1999 (2004).
15. Even-Ram, S. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 4, 909-914 (1998).
16. Versteeg, H. H. et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 68, 7219-7227 (2008).
17. Blackhart, B. D. et al. Ligand cross-reactivity within the protease-activated receptor family. J. Biol. Chem. 271, 16466-16471 (1996).
18. O'Brien, P. J. et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. 275, 13502-13509 (2000).
19. Sevigny, L. M. et al. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 31, e100-e106 (2011).
20. Jaber, M. et al. Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. Cell Mol. Life Sci. 71, 2517-2533 (2014).
21. Lemmon, M. A. & Ferguson, K. M. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem. J. 350(Pt 1): 1-18 (2000).
22. Rebecchi, M. J. & Scarlata, S. Pleckstrin homology domains: a common fold with diverse functions. Annu. Rev. Biophys. Biomol. Struct. 27, 503-528 (1998).
23. Song, G., Ouyang, G. & Bao, S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. 9, 59-71 (2005).
24. Hanada, M., Feng, J. & Hemmings, B. A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim. Biophys. Acta 1697, 3-16 (2004).
25. Neet, K. & Hunter, T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1, 147-169 (1996).
26. Smith, C. I. et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 23, 436-446 (2001).
27. Cohen, I. et al. Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance. PLoS ONE 5, e11135 (2010).
28. Zeng, L. et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol. Cell Biol. 20, 9212-9224 (2000).
29. Lee, K. et al. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 8, 158 (2008).
30. Rao, S. et al. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 31, 716-727 (2012).
31. Cote, J. F., Motoyama, A. B., Bush, J. A. & Vuori, K. A novel and evolutionarily conserved PtdIns(3,4,5)P3-binding domain is necessary for DOCK180 signalling. Nat. Cell Biol. 7, 797-807 (2005).
32. McManus, E. J. et al. The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23, 2071-2082 (2004).
33. Cenni, B., Gutmann, S. & Gottar-Guillier, M. BMX and its role in inflammation, cardiovascular disease, and cancer. Int. Rev. Immunol. 31, 166-173 (2012).
34. Gottar-Guillier, M. et al. The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. J. Immunol. 186, 6014-6023 (2011).
35. Bischof, P. & Irminger-Finger, I. The human cytotrophoblastic cell, a mononuclear chameleon. Int. J. Biochem. Cell Biol. 37, 1-16 (2005).
36. Genbacev, O., Schubach, S. A. & Miller, R. K. Villous culture of first trimester human placenta - model to study extravillous trophoblast (EVT) differentiation. Placenta 13, 439-461 (1992).
37. Grisaru-Granovsky, S. et al. Protease activated receptor-1, PAR1, promotes placenta trophoblast invasion and beta-catenin stabilization. J. Cell Physiol. 218, 512-521 (2009).
38. Konishi, H., Kuroda, S. & Kikkawa, U. The pleckstrin homology domain of RAC protein kinase associates with the regulatory domain of protein kinase C zeta. Biochem. Biophys. Res. Commun. 205, 1770-1775 (1994).
39. Yao, L., Kawakami, Y. & Kawakami, T. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. Proc. Natl Acad. Sci. USA 91, 9175-9179 (1994).
40. Farhang-Fallah, J. et al. The pleckstrin homology (PH) domain-interacting protein couples the insulin receptor substrate 1 PH domain to insulin signaling pathways leading to mitogenesis and GLUT4 translocation. Mol. Cell Biol. 22, 7325-7336 (2002).
41. Myers, Jr. M. G. et al. The pleckstrin homology domain in insulin receptor substrate-1 sensitizes insulin signaling. J. Biol. Chem. 270, 11715-11718 (1995).
42. Pitcher, J. A., Touhara, K., Payne, E. S. & Lefkowitz, R. J. Pleckstrin homology domain-mediated membrane association and activation of the beta-adrenergic receptor kinase requires coordinate interaction with G beta gamma subunits and lipid. J. Biol. Chem. 270, 11707-11710 (1995).
43. Scheffzek, K. & Welti, S. Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms. FEBS Lett. 586, 2662-2673 (2012).
44. Zheng, Y., Zangrilli, D., Cerione, R. A. & Eva, A. The pleckstrin homology domain mediates transformation by oncogenic dbl through specific intracellular targeting. J. Biol. Chem. 271, 19017-19020 (1996).
45. Chen, Z. et al. Activated RhoA binds to the pleckstrin homology (PH) domain of PDZ-RhoGEF, a potential site for autoregulation. J. Biol. Chem. 285, 21070-21081 (2010).
46. Cohen, L. A. et al. Active Arf6 recruits ARNO/cytohesin GEFs to the PM by binding their PH domains. Mol. Biol. Cell 18, 2244-2253 (2007).
47. Lutz, S. et al. Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science 318, 1923-1927 (2007).
48. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
49. Stocker, H. et al. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295, 2088-2091 (2002).
50. Franke, T. F. et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736 (1995).
51. Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444 (2007).
52. Jia, Y. et al. Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5- trisphosphate signaling in neutrophils. Immunity 27, 453-467 (2007).
53. Jia, Y., Schurmans, S. & Luo, H. R. Regulation of innate immunity by inositol 1,3,4,5-tetrakisphosphate. Cell Cycle 7, 2803-2808 (2008).
54. Rawlings, D. J. et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261, 358-361 (1993).
55. Chen, R. et al. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat. Cell Biol. 3, 439-444 (2001).
56. Movilla, N. & Bustelo, X. R. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell Biol. 19, 7870-7885 (1999).
57. Bustelo, X. R. The VAV family of signal transduction molecules. Crit. Rev. Oncog. 7, 65-88 (1996).
58. Hollenberg, M. D. et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br. J. Pharmacol. 171, 1180-1194 (2014).
59. Zhao, P., Metcalf, M. & Bunnett, N. W. Biased signaling of protease-activated receptors. Front. Endocrinol. (Lausanne) 5, 67, 1-16 (2014).
60. Mihara, K., Ramachandran, R., Renaux, B., Saifeddine, M. & Hollenberg, M. D. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J. Biol. Chem. 288, 32979-32990 (2013).
61. Ramachandran, R. et al. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J. Biol. Chem. 286, 24638-24648 (2011).
62. Zhao, P. et al. Neutrophil elastase activates protease-activated receptor-2 (PAR2) and transient receptor potential vanilloid 4 (TRPV4) to cause inflammation and pain. J. Biol. Chem. 290, 13875-13887 (2015).
63. Seatter, M. J. et al. The role of the C-terminal tail in protease-activated receptor-2-mediated Ca2+ signalling, proline-rich tyrosine kinase-2 activation, and mitogen-activated protein kinase activity. Cell Signal. 16, 21-29 (2004).
64. Rallabhandi, P. et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J. Biol. Chem. 283, 24314-24325 (2008).
65. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000).
66. Mirzadegan, T., Benko, G., Filipek, S. & Palczewski, K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42, 2759-2767 (2003).
67. Gether, U. & Kobilka, B. K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979-17982 (1998).
68. Swift, S. et al. Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J. Biol. Chem. 281, 4109-4116 (2006).
69. Adams, M. N., Christensen, M. E., He, Y., Waterhouse, N. J. & Hooper, J. D. The role of palmitoylation in signalling, cellular trafficking and plasma membrane localization of protease-activated receptor-2. PLoS ONE 6, e28018 (2011).